Latest Breaking News On - Director developmental therapeutics - Page 1 : comparemela.com

Polaris Group Initiates Phase 3 Trial: First Patient Successfully Dosed with ADI-PEG 20/Placebo plus Gemcitabine and Docetaxel for Difficult-to-Treat Leiomyosarcoma (LMS) -December 04, 2023 at 07:02 am EST

TAIPEI, Taiwan and SAN DIEGO, Dec. 04, 2023 Polaris Group , today announced that the first patient is successfully dosed in a pivotal Phase 3 trial that combines ADI-PEG 20 or placebo with.